Cardiotoxicity Assessment and Reduction Through Exercise in BREAST Cancer
NCT07405385 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44
Last updated 2026-02-12
Summary
The CARE-BREAST study is a randomized, controlled clinical trial designed to evaluate the cardioprotective effects of a supervised exercise program in breast cancer survivors. Many life-saving breast cancer treatments, such as anthracyclines and targeted therapies like trastuzumab, are known to be cardiotoxic, potentially causing long-term damage to the heart and a significant decline in cardiorrespirator fitness. This damage, known as Cancer Therapy-Related Cardiac Dysfunction (CTRCD), can manifest months or even years after treatment ends, with the highest risk occurring during the first year of survivorship. This trial focuses on a critical "recovery window," recruiting women aged 30 to 70 who completed cardiotoxic treatments between six months and one year prior to joining the study.
The study operates on the primary hypothesis that breast cancer survivors who complete a 16-week supervised, combined exercise program will show significant improvements in myocardial function-specifically measured through the Left Ventricular Ejection Fraction (LVEF) and Global Longitudinal Strain (GLS)-as well as overall aerobic capacity (VO2max) when compared to a control group. The trial aims to determine if structured exercise can mitigate the subclinical heart damage caused by chemotherapy and improve the patient's physical health and quality of life during the transition to long-term survivorship.
Participants are randomly assigned to one of two groups. The intervention group participates in a 16-week program consisting of two weekly supervised sessions at a specialized exercise unit. Each session, lasting between 55 and 85 minutes, includes a combination of strength training and aerobic exercise tailored to each participant's individual fitness level. The control group receives standard educational materials via email regarding healthy lifestyle habits and exercise guidelines for cancer survivors but does not participate in the supervised training sessions.
To measure the study's impact, all participants undergo comprehensive medical evaluations before and after the 16-week period, including heart imaging via echocardiogram, blood tests to check for cardiac biomarkers like troponin, and a maximal exercise test to assess lung and heart capacity. By comparing these results between the two groups, the research team hopes to generate high-quality evidence that can be used to establish specific exercise prescriptions as a standard part of follow-up care for breast cancer survivors, ultimately helping to protect their heart health and improve their long-term survival outcomes.
Conditions
Interventions
- BEHAVIORAL
-
Control
Participants assigned to the control group receive standard care typically provided to patients in this phase of recovery. Instead of a supervised exercise program, these individuals are sent educational materials via email. This material consists of a video and official documents containing basic guidelines and recommendations for a healthy lifestyle, based on standards from the World Health Organization (WHO) and the American College of Sports Medicine (ACSM) for cancer survivors. The documents provide general instructions on physical activity, reducing sedentary behavior, and maintaining overall health habits. Like the intervention group, participants in the control group undergo all clinical and functional evaluations at the start of the study, after 16 weeks, and during a 3-month follow-up.
- BEHAVIORAL
-
Exercise
The intervention consists of a supervised, in-person, combined exercise program lasting 16 consecutive weeks, conducted at a specialized exercise unit. Participants attend two sessions per week, with at least 48 hours of recovery between sessions, and each session lasts between 55 and 85 minutes. The program follows a "combined" methodology, meaning every session integrates both resistance (strength) and aerobic training. To ensure safety and precision, sessions are led by a graduate in Physical Activity and Sport Sciences with specialized training in oncology, and participants work in small groups of 6 to 8 people. Each session is structured into four distinct parts: a 10-minute warm-up involving low-to-moderate intensity activity and joint mobility; a resistance training block; an aerobic training block; and a cool-down featuring static stretching for 30-40 seconds per muscle group. The resistance training portion utilizes a "full body" approach.
Sponsors & Collaborators
-
University of Castilla-La Mancha
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-09-30
- Primary Completion
- 2027-08-31
- Completion
- 2027-12-31
Countries
- Spain
Study Locations
More Related Trials
-
Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.
NCT03027063 ·Status: COMPLETED ·Phase: NA
-
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
NCT05078190 ·Status: ACTIVE_NOT_RECRUITING
-
Effect of Concomitant Radiotherapy and Trastuzumab on Cardiotoxicity of Patients Treated for Early Breast Cancer
NCT01572883 ·Status: COMPLETED
-
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
NCT04962425 ·Status: UNKNOWN
-
CARDIOCARE Prospective Clinical Study
NCT06334445 ·Status: RECRUITING
-
CARdiac Function Evaluation in Breast Cancer Patients
NCT03266809 ·Status: COMPLETED
-
MIBG Scintigraphy and Strain Echocardiography in the Detection of Subclinical Cardiovascular Effects One Year After (Neo)Adjuvant Breast Cancer Treatment With Docetaxel, Doxorubicin and Cyclophosphamide (TAC): a Pilot Study
NCT01246856 ·Status: UNKNOWN
-
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
NCT05732051 ·Status: RECRUITING ·Phase: PHASE2
-
Exercise for Ameliorating Chemotherapy Cardiotoxicity
NCT06595316 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Caloric Restriction and Exercise for Protection From Anthracycline Toxic Effects
NCT03131024 ·Status: COMPLETED ·Phase: NA
-
Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients
NCT00806507 ·Status: COMPLETED
-
Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients
NCT00485979 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab
NCT04961307 ·Status: UNKNOWN
-
Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
NCT06282796 ·Status: RECRUITING
-
Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy
NCT05019365 ·Status: UNKNOWN
-
Early Cardiac Toxicity of Adjuvant CT in Elderly BC.
NCT01301040 ·Status: TERMINATED ·Phase: PHASE2
-
JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year
NCT06930521 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
NCT00944047 ·Status: COMPLETED ·Phase: PHASE2
-
Cardiotoxicity of Adjuvant Trastuzumab
NCT00858039 ·Status: COMPLETED
-
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
NCT00875238 ·Status: COMPLETED
-
Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.
NCT06387901 ·Status: RECRUITING
-
Pilot Study to Evaluate the Prevention and Safety of Doxorubicin-induced Cardiomyopathy Using Extracorporeal Shock Waves
NCT05584163 ·Status: UNKNOWN ·Phase: NA
-
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
NCT00436566 ·Status: COMPLETED ·Phase: PHASE2
-
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
NCT04305613 ·Status: ACTIVE_NOT_RECRUITING
-
Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer
NCT02102438 ·Status: WITHDRAWN ·Phase: NA